Inmaculada C. P.
- Country
- Spain
- Department
- Pediatric Rheumatology Unit
Research Overview
- Pharmacokinetics, Safety, and Tolerability of Filgotinib in Pediatric Patients with Juvenile Idiopathic Arthritis: A Multicenter, Open-Label Study
- Evaluation of Romosozumab Versus Bisphosphonates in Pediatric Osteogenesis Imperfecta: A Phase 3, Open-Label, Multicenter, Randomized Study
- Efficacy and Safety Evaluation of Apremilast in Pediatric Patients with Active Oral Ulcers Associated with Behçet's Disease: A Phase 3, Multicenter, Double-blind Study
Data & Insights
Has run more than one trial at 9 of 63 partner sites.
Specializations
Pediatric Rheumatology
This investigator specializes in treating various forms of juvenile idiopathic arthritis (JIA), including systemic JIA and juvenile psoriatic arthritis. Their research encompasses innovative therapeutic approaches for young patients with rheumatic conditions.
- Personalized medicine approaches for JIA treatment
- Biomarker-guided therapy withdrawal strategies
- Advanced imaging in pediatric rheumatology
Autoimmune Disorders
The investigator focuses on treating pediatric autoimmune conditions, with particular emphasis on systemic lupus erythematosus (SLE) and Behçet's Disease. Their work includes evaluating novel therapeutic agents for these challenging conditions.
- Pediatric lupus management
- Oral ulcers in Behçet's Disease
- Quality of life assessments in chronic conditions
Rare Diseases
Research interests extend to rare pediatric conditions, particularly fibrodysplasia ossificans progressiva (FOP) and complex rheumatic disorders. The investigator evaluates innovative therapeutic approaches for these challenging conditions.
- Heterotopic ossification treatment
- Novel therapeutic agents for rare diseases
- Long-term safety monitoring
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.